The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Stepanov I.A.

Irkutsk State Medical University

beloborodov V.A.

Irkutsk State Medical University

Shameeva M.A.

Irkutsk State Medical University

Overcoming the blood-brain barrier as a factor for increasing the efficiency of drug therapy for glioblastoma

Authors:

Stepanov I.A., beloborodov V.A., Shameeva M.A.

More about the authors

Journal: P.A. Herzen Journal of Oncology. 2023;12(2): 56‑65

DOI: 10.17116/onkolog20231202156

Read: 2798 times

Download PDF (RU)
Contact the author
Table of contents

OVERCOMING THE BLOOD-BRAIN BARRIER AS A FACTOR FOR INCREASING THE EFFICIENCY OF DRUG THERAPY FOR GLIOBLASTOMA
OVERCOMING THE BLOOD-BRAIN BARRIER AS A FACTOR FOR INCREASING THE EFFICIENCY OF DRUG THERAPY FOR GLIOBLASTOMA

To cite this article:

Stepanov IA, beloborodov VA, Shameeva MA. Overcoming the blood-brain barrier as a factor for increasing the efficiency of drug therapy for glioblastoma. P.A. Herzen Journal of Oncology. 2023;12(2):56‑65. (In Russ.)
https://doi.org/10.17116/onkolog20231202156

Подписка 2026 Онкология. Журнал им. П.А. Герцена (P.A. Herzen Journal of Oncology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Anti­gen rece­ptors in the deve­lopment of CAR-T cells for glioblastoma immu­notherapy. P.A. Herzen Journal of Onco­logy. 2024;(6):91-95
The choice of radiotherapy dose fractionation regi­men for grade 4 gliomas depe­nding on the status of MGMT. P.A. Herzen Journal of Onco­logy. 2025;(1):13-18
Radiation therapy with focal dose esca­lation in the treatment of glioblastoma. P.A. Herzen Journal of Onco­logy. 2025;(2):64-69
A Novel Rat Glioblastoma 101/8 Model: A Comparative PET-CT Study with C6 Rat model. Burdenko's Journal of Neurosurgery. 2024;(6):54-62
Modern concepts of preeclampsia, taking into account the role of the permeability of the hema­toencephalic barrier. Russian Bulletin of Obstetrician-Gynecologist. 2025;(1):11-18
The effect of Mexi­dol on the level of neurogenesis markers in acute cere­brovascular acci­dent in the expe­riment. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):107-112
Therapeutic pote­ntial of quercetin and its deri­vatives against COVID-19. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):44-50
Dyna­mics of permeability of the blood-brain barrier after FUS thalamotomy acco­rding to contrast-enhanced MRI. Burdenko's Journal of Neurosurgery. 2025;(4):51-60
Glymphatic system in health and disease: a narrative review. Burdenko's Journal of Neurosurgery. 2025;(4):112-118
TERTp muta­tion screening using digi­tal droplet PCR of collection of 52 paired DNA samples from blood plasma and tumor tissue in patients with glioblastoma. Burdenko's Journal of Neurosurgery. 2025;(5):87-95
Abstract:

Gliomas are the most common group of primary brain tumors, accounting for at least 80% of all types of central nervous system neoplasias. High-grade gliomas deserve particular attention due to the unfavorable prognosis of patient survival. Despite the use of the standard treatment protocol for patients with glioblastoma, which is based on surgical treatment, by achieving the maximum degree of tumor tissue resection, on radiation therapy and chemotherapy, only 5% of the patients reach the 5-year survival threshold. One of the main problems of modern fundamental oncology is to overcome the blood-brain barrier (BBB) using various drugs used in patients with central nervous system neoplasias. Literature searching in the Russian and foreign databases has demonstrated that there are several studies of ways to overcome the BBB with various anticancer drugs that are used for high-grade gliomas, including glioblastoma. Combining the results of these studies has been an impetus for writing this literature review.

Keywords:

high-grade gliomas
glioblastoma
blood-brain barrier
blood-brain-tumor barrier
drug delivery

Authors:

Stepanov I.A.

Irkutsk State Medical University

beloborodov V.A.

Irkutsk State Medical University

Shameeva M.A.

Irkutsk State Medical University

Received:

10.05.2022

Accepted:

20.06.2022

Close metadata

References:

  1. Molinaro AM, Taylor JW, Wiencke JK, Wrensch MR. Genetic and molecular epidemiology of adult diffuse glioma. Nat Rev Neurol. 2019;15(7):405‐417.  https://doi.org/10.1038/s41582-019-0220-2
  2. Ostrom QT, Gittleman H, Stetson L, Virk SM, Barnholtz-Sloan JS. Epidemiology of gliomas. Cancer Treat Res. 2015;163:1‐14.  https://doi.org/10.1007/978-3-319-12048-5_1
  3. Hori T, Ishida A, Aihara Y, Matsuo S, Yoshimoto H, Shiramizu H. Surgery of critically located intracranial gliomas. Prog Neurol Surg. 2018;30:186‐203.  https://doi.org/10.1159/000464396
  4. Wesseling P, Capper D. WHO 2016 Classification of gliomas. Neuropathol Appl Neurobiol. 2018;44(2):139‐150.  https://doi.org/10.1111/nan.12432
  5. Alexander BM, Cloughesy TF. Adult glioblastoma. J Clin Oncol. 2017;35(21):2402‐2409. https://doi.org/10.1200/JCO.2017.73.0119
  6. Danilov RK, ed. Rukovodstvo po gistologii. 2nd ed. Vol.1. SPb.: SpetsLit; 2011. (In Russ.).
  7. Bauer M, Karch R, Zeitlinger M, Philippe C, Römermann K, Stanek J, Maier-Salamon A, Wadsak W, Jäger W, Hacker M, et al. Approaching complete inhibition of P-glycoprotein at the human blood-brain barrier: an (R)-[11C] verapamil PET study. J Cereb Blood Flow Metab. 2015;35(5):743‐746.  https://doi.org/10.1038/jcbfm.2015.19
  8. Ben-Zvi A, Lacoste B, Kur E, Andreone BJ, Mayshar Y, Yan H, Gu C. Andreone BJ, Mayshar Y, Yan H, et al. Mfsd2a is critical for the formation and function of the blood-brain barrier. Nature. 2014;509(7501):507‐511.  https://doi.org/10.1038/nature13324
  9. Cordon-Cardo C, O’Brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed MR, Bertino JR. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA. 1989;86(2):695‐698.  https://doi.org/10.1073/pnas.86.2.695
  10. Kurnik D, Sofowora GG, Donahue JP, Nair UB, Wilkinson GR, Wood AJ, Muszkat M. Tariquidar, a selective P-glycoprotein inhibitor, does not potentiate loperamide’s opioid brain effects in humans despite full inhibition of lymphocyte P-glycoprotein. Anesthesiology. 2008;109(6):1092‐1099. https://doi.org/10.1097/ALN.0b013e31818d8f28
  11. Kicielinski KP, Chiocca EA, Yu JS, Gill GM, Coffey M, Markert JM. Phase 1 clinical trial of intratumoral reovirus infusion for the treatment of recurrent malignant gliomas in adults. Mol Ther. 2014;22(5):1056‐1062. https://doi.org/10.1038/mt.2014.21
  12. Furtado D, Björnmalm M, Ayton S, Bush AI, Kempe K, Caruso F. Overcoming the blood-brain barrier: the role of nanomaterials in treating neurological diseases. Adv Mater. 2018;30(46):e1801362. https://doi.org/10.1002/adma.201801362
  13. van Tellingen O, Yetkin-Arik B, de Gooijer MC, Wesseling P, Wurdinger T, de Vries HE. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment. Drug Resist Updat. 2015;19:1‐12.  https://doi.org/10.1016/j.drup.2015.02.002
  14. Daneman R, Prat A. The blood-brain barrier. Cold Spring Harb Perspect Biol. 2015;7(1):a020412. https://doi.org/10.1101/cshperspect.a020412
  15. Obermeier B, Verma A, Ransohoff RM. The blood-brain barrier. Handb Clin Neurol. 2016;133:39‐59.  https://doi.org/10.1016/B978-0-444-63432-0.00003-7
  16. Pardridge WM. CSF, blood-brain barrier, and brain drug delivery. Expert Opin Drug Deliv. 2016;13(7):963‐975.  https://doi.org/10.1517/17425247.2016.1171315
  17. Alvarez JI, Dodelet-Devillers A, Kebir H, Ifergan I, Fabre PJ, Terouz S, Sabbagh M, Wosik K, Bourbonnière L, Bernard M, et al. The Hedgehog pathway promotes blood-brain barrier integrity and CNS immune quiescence. Science. 2011;334(6063):1727‐1731. https://doi.org/10.1126/science.1206936
  18. Pais TF, Penha-Gonçalves C. Brain endothelium: the «Innate Immunity Response Hypothesis» in cerebral malaria pathogenesis. Front Immunol. 2019;9:3100. https://doi.org/10.3389/fimmu.2018.03100
  19. Zihni C, Mills C, Matter K, Balda MS. Tight junctions: from simple barriers to multifunctional molecular gates. Nat Rev Mol Cell Biol. 2016;17(9):564‐580.  https://doi.org/10.1038/nrm.2016.80
  20. Tietz S, Engelhardt B. Brain barriers: crosstalk between complex tight junctions and adherens junctions. J Cell Biol. 2015;209(4):493‐506.  https://doi.org/10.1083/jcb.201412147
  21. Van Itallie CM, Anderson JM. Architecture of tight junctions and principles of molecular composition. Semin Cell Dev Biol. 2014;36:157‐165.  https://doi.org/10.1016/j.semcdb.2014.08.011
  22. König J, Müller F, Fromm MF. Transporters and drug-drug interactions: important determinants of drug disposition and effects. Pharmacol Rev. 2013;65(3):944‐966.  https://doi.org/10.1124/pr.113.007518
  23. Shitara Y, Maeda K, Ikejiri K, Yoshida K, Horie T, Sugiyama Y. Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption. Biopharm Drug Dispos. 2013;34(1):45‐78.  https://doi.org/10.1002/bdd.1823
  24. van de Steeg E, van Esch A, Wagenaar E, van der Kruijssen CM, van Tellingen O, Kenworthy KE, Schinkel AH. High impact of Oatp1a/1b transporters on in vivo disposition of the hydrophobic anticancer drug paclitaxel. Clin Cancer Res. 2011;17(2):294‐301.  https://doi.org/10.1158/1078-0432.CCR-10-1980
  25. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta. 1976;455(1):152‐162.  https://doi.org/10.1016/0005-2736(76)90160-7
  26. Choi YH, Yu AM. ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development. Curr Pharm Des. 2014;20(5):793‐807.  https://doi.org/10.2174/138161282005140214165212
  27. Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, Mol CA, van der Valk MA, Robanus-Maandag EC, te Riele HP, et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell. 1994;77(4):491‐502.  https://doi.org/10.1016/0092-8674(94)90212-7
  28. Demeule M, Régina A, Jodoin J, Laplante A, Dagenais C, Berthelet F, Moghrabi A, Béliveau R. Drug transport to the brain: key roles for the efflux pump P-glycoprotein in the blood-brain barrier. Vascul Pharmacol. 2002;38(6):339‐348.  https://doi.org/10.1016/s1537-1891(02)00201-x
  29. de Vries NA, Zhao J, Kroon E, Buckle T, Beijnen JH, van Tellingen O. P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan. Clin Cancer Res. 2007;13(21):6440‐6449. https://doi.org/10.1158/1078-0432.CCR-07-1335
  30. Durmus S, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH. Oral availability and brain penetration of the B-RAFV600E inhibitor vemurafenib can be enhanced by the P-GLYCOprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar. Mol Pharm. 2012;9(11):3236‐3245. https://doi.org/10.1021/mp3003144
  31. Gil-Martins E, Barbosa DJ, Silva V, Remião F, Silva R. Dysfunction of ABC transporters at the blood-brain barrier: role in neurological disorders. Pharmacol Ther. 2020;213:107554. https://doi.org/10.1016/j.pharmthera.2020.107554
  32. Slåtsve AM, Ravna AW, Lyså RA, Sager G. ABC-transportørenes betydning for effekt og omsetning av legemidler. [ABC transporters’ impact on effect and metabolism of drugs]. Tidsskr Nor Laegeforen. 2011;131(11):1084‐1087. (In Norwegian). https://doi.org/10.4045/tidsskr.10.0675
  33. Strazielle N, Ghersi-Egea JF. Efflux transporters in blood-brain interfaces of the developing brain. Front Neurosci. 2015;9:21.  https://doi.org/10.3389/fnins.2015.00021
  34. Chaves C, Remiao F, Cisternino S, Decleves X. Opioids and the blood-brain barrier: a dynamic interaction with consequences on drug disposition in brain. Curr Neuropharmacol. 2017;15(8):1156‐1173. https://doi.org/10.2174/1570159X15666170504095823
  35. Ose A, Ito M, Kusuhara H, Yamatsugu K, Kanai M, Shibasaki M, Hosokawa M, Schuetz JD, Sugiyama Y. Limited brain distribution of [3R,4R,5S]-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate phosphate (Ro 64-0802), a pharmacologically active form of oseltamivir, by active efflux across the blood-brain barrier mediated by organic anion transporter 3 (Oat3/Slc22a8) and multidrug resistance-associated protein 4 (Mrp4/Abcc4). Drug Metab Dispos. 2009;37(2):315‐321.  https://doi.org/10.1124/dmd.108.024018
  36. Lin F, de Gooijer MC, Hanekamp D, Brandsma D, Beijnen JH, van Tellingen O. Targeting core (mutated) pathways of high-grade gliomas: challenges of intrinsic resistance and drug efflux. CNS Oncol. 2013;2(3):271‐288.  https://doi.org/10.2217/cns.13.15
  37. Kondo T. Molecular mechanisms involved in gliomagenesis. Brain Tumor Pathol. 2017;34(1):1‐7.  https://doi.org/10.1007/s10014-017-0278-8
  38. Groothuis DR. The blood-brain and blood-tumor barriers: a review of strategies for increasing drug delivery. Neuro Oncol. 2000;2(1):45‐59.  https://doi.org/10.1093/neuonc/2.1.45
  39. Machein MR, Kullmer J, Fiebich BL, Plate KH, Warnke PC. Vascular endothelial growth factor expression, vascular volume, and, capillary permeability in human brain tumors. Neurosurgery. 1999;44(4):732-740; discussion 740-741.  https://doi.org/10.1097/00006123-199904000-00022
  40. Watkins S, Robel S, Kimbrough IF, Robert SM, Ellis-Davies G, Sontheimer H. Disruption of astrocyte-vascular coupling and the blood-brain barrier by invading glioma cells. Nat Commun. 2014;5:4196. https://doi.org/10.1038/ncomms5196
  41. Byval’tsev VA, Stepanov IA, Belykh YuG, Yarullina AI. Molecular aspects of angiogenesis in brain glioblastomas. Voprosy Onkologii. 2017;63(1):19-27. (In Russ.). https://doi.org/10.37469/0507-3758-2017-63-1-19-27
  42. Korfel A, Thiel E. Targeted therapy and blood-brain barrier. Recent Results Cancer Res. 2007;176:123‐133.  https://doi.org/10.1007/978-3-540-46091-6_10
  43. Ningaraj NS, Rao M, Hashizume K, Asotra K, Black KL. Regulation of blood-brain tumor barrier permeability by calcium-activated potassium channels. J Pharmacol Exp Ther. 2002;301(3):838‐851.  https://doi.org/10.1124/jpet.301.3.838
  44. Nishio S, Ohta M, Abe M, Kitamura K. Microvascular abnormalities in ethylnitrosourea (ENU)-induced rat brain tumors: structural basis for altered blood-brain barrier function. Acta Neuropathol. 1983;59(1):1‐10.  https://doi.org/10.1007/BF00690311
  45. Lin F, de Gooijer MC, Roig EM, Buil LC, Christner SM, Beumer JH, Würdinger T, Beijnen JH, van Tellingen O. ABCB1, ABCG2, and PTEN determine the response of glioblastoma to temozolomide and ABT-888 therapy. Clin Cancer Res. 2014;20(10):2703‐2713. https://doi.org/10.1158/1078-0432.CCR-14-0084
  46. Rapoport SI. Effect of concentrated solutions on blood-brain barrier. Am J Physiol. 1970;219(1):270‐274.  https://doi.org/10.1152/ajplegacy.1970.219.1.270
  47. Rapoport SI, Hori M, Klatzo I. Testing of a hypothesis for osmotic opening of the blood-brain barrier. Am J Physiol. 1972;223(2):323‐331.  https://doi.org/10.1152/ajplegacy.1972.223.2.323
  48. Siegal T, Rubinstein R, Bokstein F, Schwartz A, Lossos A, Shalom E, Chisin R, Gomori JM. In vivo assessment of the window of barrier opening after osmotic blood-brain barrier disruption in humans. J Neurosurg. 2000;92(4):599‐605.  https://doi.org/10.3171/jns.2000.92.4.0599
  49. Angelov L, Doolittle ND, Kraemer DF, Siegal T, Barnett GH, Peereboom DM, Stevens G, McGregor J, Jahnke K, Lacy CA, et al. Blood-brain barrier disruption and intra-arterial methotrexate-based therapy for newly diagnosed primary CNS lymphoma: a multi-institutional experience. J Clin Oncol. 2009;27(21):3503-3509. https://doi.org/10.1200/jco.2008.19.3789
  50. Burkhardt JK, Riina H, Shin BJ, Christos P, Kesavabhotla K, Hofstetter CP, Tsiouris AJ, Boockvar JA. Intra-arterial delivery of bevacizumab after blood-brain barrier disruption for the treatment of recurrent glioblastoma: progression-free survival and overall survival. World Neurosurg. 2012;77(1):130‐134.  https://doi.org/10.1016/j.wneu.2011.05.056
  51. Raymond JJ, Robertson DM, Dinsdale HB. Pharmacological modification of bradykinin induced breakdown of the blood-brain barrier. Can J Neurol Science. 1986;13(3):214-220.  https://doi.org/10.1017/s0317167100036301
  52. Elliott PJ, Hayward NJ, Huff MR, Nagle TL, Black KL, Bartus RT. Unlocking the blood-brain barrier: a role for RMP-7 in brain tumor therapy. Exp Neurol. 1996;141(2):214‐224.  https://doi.org/10.1006/exnr.1996.0156
  53. Inamura T, Nomura T, Bartus RT, Black KL. Intracarotid infusion of RMP-7, a bradykinin analog: a method for selective drug delivery to brain tumors. J Neurosurg. 1994;81(5):752‐758.  https://doi.org/10.3171/jns.1994.81.5.0752
  54. Prados MD, Schold SC Jr, Fine HA, Jaeckle K, Hochberg F, Mechtler L, Fetell MR, Phuphanich S, Feun L, Janus TJ, et al. A randomized, double-blind, placebo-controlled, phase 2 study of RMP-7 in combination with carboplatin administered intravenously for the treatment of recurrent malignant glioma. Neuro Oncol. 2003;5(2):96‐103.  https://doi.org/10.1093/neuonc/5.2.96
  55. Warren K, Jakacki R, Widemann B, Aikin A, Libucha M, Packer R, Vezina G, Reaman G, Shaw D, Krailo M, et al. Phase II trial of intravenous lobradimil and carboplatin in childhood brain tumors: a report from the Children’s Oncology Group. Cancer Chemother Pharmacol. 2006;58(3):343‐347.  https://doi.org/10.1007/s00280-005-0172-7
  56. Emerich DF, Snodgrass P, Dean R, Agostino M, Hasler B, Pink M, Xiong H, Kim BS, Bartus RT. Enhanced delivery of carboplatin into brain tumours with intravenous Cereport (RMP-7): dramatic differences and insight gained from dosing parameters. Br J Cancer. 1999;80(7):964‐970.  https://doi.org/10.1038/sj.bjc.6690450
  57. de Bruin M, Miyake K, Litman T, Robey R, Bates SE. Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR. Cancer Lett. 1999;146(2):117‐126.  https://doi.org/10.1016/s0304-3835(99)00182-2
  58. Stein WD, Bates SE, Fojo T. Intractable cancers: the many faces of multidrug resistance and the many targets it presents for therapeutic attack. Curr Drug Targets. 2004;5(4):333‐346.  https://doi.org/10.2174/1389450043345489
  59. Choo EF, Kurnik D, Muszkat M, Ohkubo T, Shay SD, Higginbotham JN, Glaeser H, Kim RB, Wood AJ, Wilkinson GR. Differential in vivo sensitivity to inhibition of P-glycoprotein located in lymphocytes, testes, and the blood-brain barrier. J Pharmacol Exp Ther. 2006;317(3):1012‐1018. https://doi.org/10.1124/jpet.105.099648
  60. Kemper EM, van Zandbergen AE, Cleypool C, Mos HA, Boogerd W, Beijnen JH, van Tellingen O. Mos HA, Boogerd W, Beijnen JH, et al. Increased penetration of paclitaxel into the brain by inhibition of P-Glycoprotein. Clin Cancer Res. 2003;9(7):2849‐2855.
  61. Pardridge WM. Drug transport across the blood-brain barrier. J Cereb Blood Flow Metab. 2012;32(11):1959‐1972. https://doi.org/10.1038/jcbfm.2012.126
  62. Drappatz J, Brenner A, Wong ET, Eichler A, Schiff D, Groves MD, Mikkelsen T, Rosenfeld S, Sarantopoulos J, Meyers CA, et al. Phase I study of GRN1005 in recurrent malignant glioma. Clin Cancer Res. 2013;19(6):1567‐1576. https://doi.org/10.1158/1078-0432.CCR-12-2481
  63. Gaillard PJ, Kerklaan BM, Aftimos P, Altintas S, Jager A, Gladdines W, Lonnqvist F, Soetekouw P, Verheul H, Awada A, et al. Abstract CT216: phase I dose escalating study of 2B3-101, glutathione PEGylated liposomal doxorubicin, in patients with solid tumors and brain metastases or recurrent malignant glioma. Cancer Res. 2014;74(19 suppl):CT216. https://doi.org/10.1158/1538-7445.am2014-ct216
  64. Allhenn D, Boushehri MA, Lamprecht A. Drug delivery strategies for the treatment of malignant gliomas. Int J Pharm. 2012;436(1-2):299‐310.  https://doi.org/10.1016/j.ijpharm.2012.06.025
  65. Bidros DS, Liu JK, Vogelbaum MA. Future of convection-enhanced delivery in the treatment of brain tumors. Future Oncol. 2010;6(1):117‐125.  https://doi.org/10.2217/fon.09.135
  66. Buonerba C, Di Lorenzo G, Marinelli A, Federico P, Palmieri G, Imbimbo M, Conti P, Peluso G, De Placido S, Sampson JH. A comprehensive outlook on intracerebral therapy of malignant gliomas. Crit Rev Oncol Hematol. 2011;80(1):54‐68.  https://doi.org/10.1016/j.critrevonc.2010.09.001
  67. Brown CB, Jacobs S, Johnson MP, Southerland C, Threatt S. Convection-enhanced delivery in the treatment of glioblastoma. Semin Oncol Nurs. 2018;34(5):494‐500.  https://doi.org/10.1016/j.soncn.2018.10.004
  68. Mehta AM, Sonabend AM, Bruce JN. Convection-enhanced delivery. Neurotherapeutics. 2017;14(2):358‐371.  https://doi.org/10.1007/s13311-017-0520-4
  69. Jahangiri A, Chin AT, Flanigan PM, Chen R, Bankiewicz K, Aghi MK. Convection-enhanced delivery in glioblastoma: a review of preclinical and clinical studies. J Neurosurg. 2017;126(1):191‐200.  https://doi.org/10.3171/2016.1.JNS151591
  70. Luther N, Zhou Z, Zanzonico P, Cheung NK, Humm J, Edgar MA, Souweidane MM. The potential of theragnostic ¹²⁴I-8H9 convection-enhanced delivery in diffuse intrinsic pontine glioma. Neuro Oncol. 2014;16(6):800‐806.  https://doi.org/10.1093/neuonc/not298
  71. Sonabend AM, Carminucci AS, Amendolara B, Bansal M, Leung R, Lei L, Realubit R, Li H, Karan C, Yun J, et al. Convection-enhanced delivery of etoposide is effective against murine proneural glioblastoma. Neuro Oncol. 2014;16(9):1210‐1219. https://doi.org/10.1093/neuonc/nou026
  72. Sewing AC, Caretti V, Lagerweij T, Schellen P, Jansen MH, van Vuurden DG, Idema S, Molthoff CF, Vandertop WP, Kaspers GJ, et al. Convection enhanced delivery of carmustine to the murine brainstem: a feasibility study. J Neurosci Methods. 2014;238:88‐94.  https://doi.org/10.1016/j.jneumeth.2014.09.020
  73. Yang W, Barth RF, Huo T, Nakkula RJ, Weldon M, Gupta N, Agius L, Grecula JC. Radiation therapy combined with intracerebral administration of carboplatin for the treatment of brain tumors. Radiat Oncol. 2014;9:25.  https://doi.org/10.1186/1748-717x-9-25
  74. Huo T, Barth RF, Yang W, Nakkula RJ, Koynova R, Tenchov B, Chaudhury AR, Agius L, Boulikas T, Elleaume H, et al. Preparation, biodistribution and neurotoxicity of liposomal cisplatin following convection enhanced delivery in normal and F98 glioma bearing rats. PLoS One. 2012;7(11):e48752. https://doi.org/10.1371/journal.pone.0048752
  75. Duebgen M, Martinez-Quintanilla J, Tamura K, Hingtgen S, Redjal N, Wakimoto H, Shah K. Stem cells loaded with multimechanistic oncolytic herpes simplex virus variants for brain tumor therapy. J Natl Cancer Inst. 2014;106(6):dju090. https://doi.org/10.1093/jnci/dju090
  76. Lidar Z, Mardor Y, Jonas T, Pfeffer R, Faibel M, Nass D, Hadani M, Ram Z. Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a phase I/II clinical study. J Neurosurg. 2004;100(3):472‐479.  https://doi.org/10.3171/jns.2004.100.3.0472
  77. Bruce JN, Fine RL, Canoll P, Yun J, Kennedy BC, Rosenfeld SS, Sands SA, Surapaneni K, Lai R, Yanes CL, et al. Regression of recurrent malignant gliomas with convection-enhanced delivery of topotecan. Neurosurgery. 2011;69(6):1272‐1279; discussion 1279-1280. https://doi.org/10.1227/NEU.0b013e3182233e24
  78. Saito R, Sonoda Y, Kumabe T, Nagamatsu K, Watanabe M, Tominaga T. Regression of recurrent glioblastoma infiltrating the brainstem after convection-enhanced delivery of nimustine hydrochloride. J Neurosurg Pediatr. 2011;7(5):522-526.  https://doi.org/10.3171/2011.2.peds10407
  79. Bogdahn U, Hau P, Stockhammer G, Venkataramana NK, Mahapatra AK, Suri A, Balasubramaniam A, Nair S, Oliushine V, Parfenov V, et al. Targeted therapy for high-grade glioma with the TGF-β2 inhibitor trabedersen: results of a randomized and controlled phase IIb study. Neuro Oncol. 2011;13(1):132‐142.  https://doi.org/10.1093/neuonc/noq142
  80. Markert JM, Razdan SN, Kuo HC, Cantor A, Knoll A, Karrasch M, Nabors LB, Markiewicz M, Agee BS, Coleman JM, et al. A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses. Mol Ther. 2014;22(5):1048‐1055. https://doi.org/10.1038/mt.2014.22
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.